What is the address of Dr. Dopchie Cathérine, oncoloog?

The registered office of Dr. Dopchie Cathérine, oncoloog is located at Moortelstraat 38, 9600 Ronse.

Is Dr. Dopchie Cathérine, oncoloog still active?

Yes. According to the CBE (28 September 2026) Dr. Dopchie Cathérine, oncoloog is active, legal situation “Normale toestand”, started on 3 October 2014.

Is Dr. Dopchie Cathérine, oncoloog registered on Peppol?

No, Dr. Dopchie Cathérine, oncoloog is currently not registered on the Peppol network.

What is the enterprise number of Dr. Dopchie Cathérine, oncoloog?

The enterprise number of Dr. Dopchie Cathérine, oncoloog is BE0563603454.

When was Dr. Dopchie Cathérine, oncoloog founded?

Dr. Dopchie Cathérine, oncoloog was founded on 3 October 2014.

Who are the directors of Dr. Dopchie Cathérine, oncoloog?

According to the 2025 annual accounts, the directors of Dr. Dopchie Cathérine, oncoloog are: Catherine Dopchie.

Is Dr. Dopchie Cathérine, oncoloog a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 October 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Dopchie Cathérine, oncoloog make in 2025?

Dr. Dopchie Cathérine, oncoloog posted a profit after taxes of € 91,935 in financial year 2025.

What is the revenue of Dr. Dopchie Cathérine, oncoloog?

As a small company, Dr. Dopchie Cathérine, oncoloog is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 129,587.

Dr. Dopchie Cathérine, oncoloog (Private Limited) - Ronse

Dossier Dr. Dopchie Cathérine, oncoloog, printed on 28 September 2026 from databakkes.be/en/0563603454/dr-dopchie-catherine-oncoloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Dr. Dopchie Cathérine, oncoloog from Ronse, company number BE0563603454, closed financial year 2025 with a result of € 91,935 after tax. For that financial year Dr. Dopchie Cathérine, oncoloog recorded a gross margin of € 129,587 and equity of € 138,657. Compared with financial year 2024, the result moved from € 4,448 to € 91,935. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.

What it is worth Healthy

€ 138,657

▼ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 91,935

▲ € 87,487 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 248,236

▲ 17% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 160,927 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 717

▲ 68% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 17,128 Gross margin 2022: € 17,128 First fiscal year in the series	€ -19,810 Gross margin 2023: € -19,810 ▼ € 36,937 vs 2022 (€ 17,128) Unfavourable step	€ -3,401 Gross margin 2024: € -3,401 ▲ € 16,409 vs 2023 (€ -19,810) Favourable step	€ 129,587 Gross margin 2025: € 129,587 ▲ € 132,988 vs 2024 (€ -3,401) Favourable step	▲ € 132,988
Profit after taxes	€ 10,041 Profit after taxes 2022: € 10,041 First fiscal year in the series	€ -20,919 Profit after taxes 2023: € -20,919 ▼ € 30,960 vs 2022 (€ 10,041) Unfavourable step	€ 4,448 Profit after taxes 2024: € 4,448 ▲ € 25,366 vs 2023 (€ -20,919) Favourable step	€ 91,935 Profit after taxes 2025: € 91,935 ▲ € 87,487 vs 2024 (€ 4,448) Favourable step	▲ € 87,487
Equity	€ 228,119 Equity 2022: € 228,119 First fiscal year in the series	€ 205,201 Equity 2023: € 205,201 ▼ 10% vs 2022 (€ 228,119) Unfavourable step	€ 207,648 Equity 2024: € 207,648 ▲ 1% vs 2023 (€ 205,201) Favourable step	€ 138,657 Equity 2025: € 138,657 ▼ 33% vs 2024 (€ 207,648) Unfavourable step	▼ 33%
Total debts	€ 59,481 Total debts 2022: € 59,481 First fiscal year in the series	€ 50,827 Total debts 2023: € 50,827 ▼ 15% vs 2022 (€ 59,481) Favourable step	€ 11,429 Total debts 2024: € 11,429 ▼ 78% vs 2023 (€ 50,827) Favourable step	€ 115,712 Total debts 2025: € 115,712 ▲ € 104,283 vs 2024 (€ 11,429) Unfavourable step	▲ € 104,283
Cash	€ 270,842 Cash 2022: € 270,842 First fiscal year in the series	€ 248,247 Cash 2023: € 248,247 ▼ 8% vs 2022 (€ 270,842) Unfavourable step	€ 212,323 Cash 2024: € 212,323 ▼ 14% vs 2023 (€ 248,247) Unfavourable step	€ 248,236 Cash 2025: € 248,236 ▲ 17% vs 2024 (€ 212,323) Favourable step	▲ 17%
Retained profit	€ 208,119 Retained profit 2022: € 208,119 First fiscal year in the series	€ 185,201 Retained profit 2023: € 185,201 ▼ 11% vs 2022 (€ 208,119) Unfavourable step	€ 187,648 Retained profit 2024: € 187,648 ▲ 1% vs 2023 (€ 185,201) Favourable step	€ 118,657 Retained profit 2025: € 118,657 ▼ 37% vs 2024 (€ 187,648) Unfavourable step	▼ 37%
Dividend	€ 2,000 Dividend 2022: € 2,000 First fiscal year in the series	€ 2,000 Dividend 2023: € 2,000 Unchanged (€ 2,000) Unchanged	€ 2,000 Dividend 2024: € 2,000 Unchanged (€ 2,000) Unchanged	€ 160,927 Dividend 2025: € 160,927 ▲ € 158,927 vs 2024 (€ 2,000) Unchanged	▲ € 158,927
Balance sheet total	€ 287,601 Balance sheet total 2022: € 287,601 First fiscal year in the series	€ 256,027 Balance sheet total 2023: € 256,027 ▼ 11% vs 2022 (€ 287,601) Unchanged	€ 219,077 Balance sheet total 2024: € 219,077 ▼ 14% vs 2023 (€ 256,027) Unchanged	€ 254,369 Balance sheet total 2025: € 254,369 ▲ 16% vs 2024 (€ 219,077) Unchanged	▲ 16%

Key figures of Dr. Dopchie Cathérine, oncoloog, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Dopchie Cathérine, oncoloog?

What happened at Dr. Dopchie Cathérine, oncoloog in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 23, 2026 New annual accounts for financial year 2025: profit of € 91,935 (▲ € 87,487 vs 2024). Source: NBB ↗
Oct 3, 2014 New establishment in Ronse. KBO
Oct 3, 2014 Start of the company according to the CBE. KBO

In short

From € 10,041 profit in 2022 to € 91,935 profit in 2025.

Paid € 43,183 in corporate taxes since 2022.

Best year ever: 2025, with € 91,935 profit.

Paid out € 166,927 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Dopchie Cathérine, oncoloog? We notify you, reason included.

Follow Dr. Dopchie Cathérine, oncoloog

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Catherine Dopchie

Dr. Dopchie Cathérine, oncoloog

Behind Dr. Dopchie Cathérine, oncoloog is Catherine Dopchie.

See the full network in the app

Directors

According to the 2025 annual accounts

Catherine Dopchie

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Moortelstraat 38

9600 Ronse

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0563.603.454
VAT number: BE 0563.603.454
Registered office: Moortelstraat 38, 9600 Ronse
Names & denominations: Dr. Dopchie Cathérine, oncoloog
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 3 October 2014
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗